Serum Soluble CD200 Level was Higher in Patients with Bullous Pemphigoid During the Active Phase of the Disease than for Healthy Individuals

Akman-Karakas A., Yalcin A. D., Koc S., GÜMÜŞLÜ S., Ergun E., Genc G. E., ...Daha Fazla

CLINICAL LABORATORY, cilt.60, sa.7, ss.1237-1240, 2014 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 60 Sayı: 7
  • Basım Tarihi: 2014
  • Doi Numarası: 10.7754/clin.lab.2013.130744
  • Dergi Adı: CLINICAL LABORATORY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1237-1240
  • Anahtar Kelimeler: Bullous pemphigoid, CD200, serum, soluble, BP180, SCD200, OMALIZUMAB, IL-1-BETA
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Background: CD200 is a novel immunosuppressive molecule, existing both as cell membrane bound and as a soluble form in serum (sCD200), which acts to regulate inflammatory and acquired immune responses. Recently, our study group showed that sCD200 was found in serum and blister fluid in a patient with bullous pemphigoid and that anti-IgE therapy impacted those levels. We therefore planned this study to evaluate the soluble serum CD200 levels of bullous pemphigoid patients and compare it with that of healthy controls. We also analysed the association between the sCD200 levels and the clinical severity of the disease in bullous pemphigoid patients.